111 Capital Buys 9,064 Shares of Hologic, Inc. $HOLX

111 Capital raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 129.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 16,085 shares of the medical equipment provider’s stock after purchasing an additional 9,064 shares during the period. 111 Capital’s holdings in Hologic were worth $1,048,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of HOLX. Victory Capital Management Inc. grew its holdings in Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock valued at $408,283,000 after purchasing an additional 1,692,177 shares during the period. Nuance Investments LLC grew its holdings in Hologic by 623.7% during the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after purchasing an additional 931,920 shares during the period. Redwood Wealth Management Group LLC bought a new stake in Hologic during the first quarter valued at about $3,534,000. Invesco Ltd. grew its holdings in Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after purchasing an additional 764,573 shares during the period. Finally, Nuveen LLC bought a new stake in Hologic during the first quarter valued at about $30,317,000. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.5%

Shares of HOLX stock opened at $68.22 on Friday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock’s 50 day simple moving average is $66.97 and its two-hundred day simple moving average is $63.09. The company has a market cap of $15.17 billion, a PE ratio of 28.31, a price-to-earnings-growth ratio of 2.34 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business posted $1.06 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HOLX. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Hologic in a research note on Saturday, September 27th. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Finally, Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.